Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine + cytarabine in elderly AML or high-risk MDS with high early mortality risk
NL-OMON23606Phase 2Not yet recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of decitabine and cytarabine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Leiden University Medical Center. Primary endpoint: 30-day mortality. Planned start Mar 2016; status: not yet recruiting.
02
Drugs
decitabinecytarabine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NL-OMON23606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON23606.